Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06577766 | A Research Study on How NNC0638-0355, a New Medicine, Works in People Living With Overweight or Obesity | PHASE1 | ACTIVE NOT_RECRUITING | 63 | — | — | Sep 3, 2024 | Sep 24, 2026 | Mar 17, 2026 | 1 | United States |
Measured as Number of events
Measured as Number of events
| Arm | Type | Description |
|---|---|---|
| NNC0638-0355 | EXPERIMENTAL | Participants will be randomized to receive NNC0638-0355. The study will be conducted in 5 parts. Part A: Single ascending dose (SAD) Part B, C, D and E: Multiple ascending dose (MAD). |
| Placebo | PLACEBO_COMPARATOR | Participants will be randomized to receive Placebo. The study will be conducted in 5 parts. Part A: Single ascending dose (SAD). Part B, C,D and E: Multiple ascending dose (MAD). |
| Name | Type | Description |
|---|---|---|
| NNC0638-0355 | DRUG | NNC0638-0355 will be administered as a subcutaneous (s.c. under the skin) injection. |
| Placebo (NNC0638-0355) | DRUG | Placebo matching NNC0638-0355 will be administered as subcutaneous (s.c. under the skin) injection. |
Key inclusion criteria * Male or female. * Age 18-55 years (both inclusive) at the time of signing the informed consent. * BMI between 25.0 and 34.9 kg/m\^2 (both inclusive) at screening. Overweight should be due to excess adipose tissue, as judged by the investigator. * Considered to be generally ...